rs114554346 - TAOK3
Magnitude 4.5 · 1 study on file
Reported associations
-
Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events - Unknown journal (n.d.) · Unknown authors · PubMed 36186466
ABSTRACT: Apixaban is a direct oral anticoagulant, a factor Xa inhibitor, used for the prevention of ischemic stroke in patients with atrial fibrillation. Despite using recommended dosing a few patients might still experience bleeding or lack of efficacy that might be related to inappropriate drug exposure. We conducted a genome-wide association study using data from 1,325 participants in the pivotal phase three trial of apixaban with the aim to identify genetic factors affecting the pharmacokinetics of apixaban. A candidate gene analysis was also performed for pre-specified variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SULT1A1, with a subsequent analysis of all available polymorphisms within the candidate genes. Significant findings were further evaluated to assess a potential association
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
TAOK3 rs114554346 effect on apixaban metabolism Moderate
The rs114554346 variant in TAOK3 alters apixaban pharmacokinetics, affecting steady-state plasma levels and potentially impacting anticoagulation efficacy
Inform your prescriber of this variant if apixaban is prescribed or being considered